<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912466</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI322A105</org_study_id>
    <nct_id>NCT04912466</nct_id>
  </id_info>
  <brief_title>IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.</brief_title>
  <official_title>A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity&#xD;
      and primary resistance of single therapy tumor activity in subjects with advanced or&#xD;
      metastatic solid tumors who have failed standard treatment. Phase Ib study was designed to&#xD;
      evaluate the safety and initial efficacy of IBI322 in monotherapy or combination therapy in&#xD;
      subjects with advanced or metastatic solid tumors. Investigators and sponsors determine the&#xD;
      recommended dose of IBI322 for phase Ib based on PK, PD, safety and efficacy data obtained&#xD;
      during phase Ia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of DLT</measure>
    <time_frame>21 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment related AEs</measure>
    <time_frame>up to 90 days post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with response</measure>
    <time_frame>Last patient enrolled+24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker evaluation</measure>
    <time_frame>from first dose until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>positive rate of ADA&amp;NAB</measure>
    <time_frame>from first dose until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plsma concentration versus time curve(AUC)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration(Cmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance rate(CL)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the distribution volumn (Vd)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life period(t1/2)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of receptor occupancy</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte count (RET)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count (PLT)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IBI322</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Singal arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biological: IBI322</intervention_name>
    <description>Recombinant anti-human CD47/PD-L1 bispecific antibody injection</description>
    <arm_group_label>IBI322</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically/cytologically confirmed, locally advanced unresectable or metastatic&#xD;
             tumors.&#xD;
&#xD;
          2. Per RECIST1, at least one evaluable or measurable lesion.&#xD;
&#xD;
          3. Male or female subject above 18 years old, no more than 75 years old.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0&#xD;
             or 1.&#xD;
&#xD;
          5. Must have adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα&#xD;
             recombinant protein.&#xD;
&#xD;
          2. Direct coombs test was positive or have history of hemolytic anemia.&#xD;
&#xD;
          3. Subjects participating in another interventional clinical study, except for:&#xD;
             observational (non-interventional) clinical studies or survival follow-up phase of&#xD;
             interventional studies.&#xD;
&#xD;
          4. Patients who are on anticoagulants and /or require concomitant aspirin or other&#xD;
             nonsteroids anti-inflammatory medications. Patients with a history of a bleeding&#xD;
             diathesis (von Willebrand disease, end stage liver disease, hemophilia, etc.)&#xD;
&#xD;
          5. Subjects who have a history of blood transfusion within 2 weeks prior to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>No.440, Jiyan Road, Jinang City, Shandong Province, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiyun Zuo</last_name>
    <phone>021-31837200</phone>
    <email>haiyun.zuo@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Province Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huijuan Li</last_name>
      <phone>0531-67626073</phone>
      <email>ywb234@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

